Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan-Dec:30:10742484241304304.
doi: 10.1177/10742484241304304.

Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction

Tyler Shugg  1   2 , Tk Nguyen  2 , Xuesi Hua  2 , Blair Richards  3 , James Rae  4 , Robert Dess  5 , Daniel Perry  6 , Bradley Kay  7 , Salim S Hayek  6 , Monika Leja  6 , Jasmine A Luzum  2
Affiliations

Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction

Tyler Shugg et al. J Cardiovasc Pharmacol Ther. 2025 Jan-Dec.

Abstract

Background: Neurohormonal blocking drugs, like beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs), are recommended for treating anthracycline-induced left ventricular dysfunction (AILVD). However, there is limited evidence supporting their benefit. Therefore, this study evaluated associations of neurohormonal blockers and other clinical factors with recovery of left ventricular ejection fraction (LVEF) in patients with AILVD.

Methods: This retrospective chart review assessed patients treated with at least one dose of anthracycline, then had ≥10% LVEF reduction or post-anthracycline LVEF value <50%, and then had a follow-up LVEF measurement ≥90 days later. The primary endpoint was LVEF recovery (highest follow-up LVEF-lowest LVEF post-anthracycline). Variables from univariable tests with P < .1 were incorporated in a multiple linear regression model for independent factors significantly associated with LVEF recovery (P < .05).

Results: Out of 104 patients, 83% were female, 86% self-reported white race, 53% had breast cancer, median (IQR) age was 52 (22) years, and LVEF recovery was 14% (16%). The final multivariable model included 2 significant variables: beta-blocker dose after anthracycline exposure (every 25 mg increase in beta-blocker dose was associated with 5.0% increase in LVEF recovery; P = .0005) and the time between the start of the anthracycline and the lowest LVEF post-anthracycline (every 5-year increase in time was associated with 1.8% decrease in LVEF recovery; P = .0379).

Conclusions: In patients with AILVD, a higher beta-blocker dose and earlier detection of LVEF reduction post-anthracycline were significantly and independently associated with improved LVEF recovery. These findings need to be validated in a larger, independent cohort.

Keywords: aldosterone antagonist; angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; anthracycline-induced cardiomyopathy; anthracycline-induced left ventricular dysfunction‌; beta-blocker; left ventricular ejection fraction.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.A.L. is a consultant for Ariel Precision Medicine. The other authors have no conflicts of interest to disclose.

References

    1. Siegel RL, Miller KD, & Jemal A Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551 - DOI - PubMed
    1. Eichenauer DA, Aleman BMP, & André M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol. 2018;29(Suppl 4):iv19–iv29. doi:10.1093/annonc/mdy080 - DOI - PubMed
    1. Casali PG, Bielack S, & Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol. 2018;29(Suppl 4):iv79–iv95. doi:10.1093/annonc/mdy310 - DOI - PubMed
    1. Cardoso F, Kyriakides S, & Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol: Off J Eur Soc Med Oncol. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz173 - DOI - PubMed
    1. Von Hoff DD, Layard MW, & Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Internal Med. 1979;91(5):710–717. doi:10.7326/0003-4819-91-5-710 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources